The tumor microenvironment: A pitch for multiple players

Frontiers in Oncology

Volumn 3 APR, Issue , 2013, Pages

  Schiavoni, Giovanna ^a   Gabriele, Lucia ^a   Mattei, Fabrizio ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Cancer stem cells; Dendritic cells; Macrophages; Myeloid derived suppressor cells; NK cells; Solid tumors; T lymphocytes; Tumor microenvironment

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CXCL16 CHEMOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MICRORNA 21; MICRORNA 29A; MONOCYTE CHEMOTACTIC PROTEIN 1; SECONDARY LYMPHOID TISSUE CHEMOKINE; STAT1 PROTEIN; STAT3 PROTEIN; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR VACCINE; VASCULOTROPIN A;

ARTICLE; BONE MARROW CELL; CANCER STEM CELL; CELL INFILTRATION; CELL INTERACTION; CELL POPULATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GAMMA DELTA T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MACROPHAGE; MELANOMA; MOLECULAR INTERACTION; MONOCYTE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INTERACTION; SUPPRESSOR CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 84885701721     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00090     Document Type: Article

References (197)

1. Afonina, I. S., Cullen, S. P., and Martin, S. J. (2010). Cytotoxic and non-cytotoxic roles of the CTL/NK protease granzyme B. Immunol. Rev. 235, 105-116.
2. Alexe, G., Dalgin, G. S., Scanfeld, D., Tamayo, P., Mesirov, J. P., Delisi, C., et al. (2007). High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res. 67, 10669-10676.
3. Al-Shibli, K. I., Donnem, T., Al-Saad, S., Persson, M., Bremnes, R. M., and Busund, L. T. (2008). Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin. Cancer Res. 14, 5220-5227.
4. Azogui, O., Avril, M. F., Margulis, A., Guillard, M., Caillou, B., and Prade, M. (1991). Tumor-infiltrating CD3-NK cells are more effective than CD3+ T cells in killing autologous melanoma cells. J. Invest. Dermatol. 97, 425-429.
5. Badoual, C., Hans, S., Fridman, W. H., Brasnu, D., Erdman, S., and Tartour, E. (2009). Revisiting the prognostic value of regulatory T cells in patients with cancer. J. Clin. Oncol. 27, e5-e6. author reply e7.
6. Badoual, C., Hans, S., Merillon, N., Van Ryswick, C., Ravel, P., Benhamouda, N., et al. (2013). PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res. 73, 128-138.
7. Balsamo, M., Pietra, G., Vermi, W., Moretta, L., Mingari, M. C., and Vitale, M. (2012). Melanoma immunoediting by NK cells. Oncoimmunology 1, 1607-1609.
8. Bendelac, A., Savage, P. B., and Teyton, L. (2007). The biology of NKT cells. Annu. Rev. Immunol. 25, 297-336.
9. Berzofsky, J. A., and Terabe, M. (2008). NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis. J. Immunol. 180, 3627-3635.
10. Bonnet, D., and Dick, J. E. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730-737.
11. Boral, D., and Nie, D. (2012). Cancer stem cells and niche mircoenvironments. Front. Biosci. (Elite Ed.) 4, 2502-2514.
12. Bunt, S. K., Yang, L., Sinha, P., Clements, V. K., Leips, J., and Ostrand-Rosenberg, S. (2007). Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 67, 10019-10026.
13. Businaro, L., De Ninno, A., Schiavoni, G., Lucarini, V., Ciasca, G., Gerardino, A., et al. (2013). Cross talk between cancer and immune cells: exploring complex dynamics in a microfluidic environment. Lab. Chip 13, 229-239.
14. Butler, K. L., Ambravaneswaran, V., Agrawal, N., Bilodeau, M., Toner, M., Tompkins, R. G., et al. (2010). Burn injury reduces neutrophil directional migration speed in microfluidic devices. PLoS ONE 5:e11921. doi:10.1371/journal.pone.0011921
15. Carrega, P., Pezzino, G., Queirolo, P., Bonaccorsi, I., Falco, M., Vita, G., et al. (2009). Susceptibility of human melanoma cells to autologous natural killer (NK) cell killing: HLA-related effector mechanisms and role of unlicensed NK cells. PLoS ONE 4:e8132. doi:10.1371/journal.pone.0008132
16. Chan, C. J., Andrews, D. M., McLaughlin, N. M., Yagita, H., Gilfillan, S., Colonna, M., et al. (2010). DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases. J. Immunol. 184, 902-911.
17. Chaux, P., Favre, N., Bonnotte, B., Moutet, M., Martin, M., and Martin, F. (1997a). Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression. A role in the immune tolerance to antigenic tumors. Adv. Exp. Med. Biol. 417, 525-528.
18. Chaux, P., Favre, N., Martin, M., and Martin, F. (1997b). Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. Int. J. Cancer 72, 619-624.
19. Chen, P., Huang, Y., Bong, R., Ding, Y., Song, N., Wang, X., et al. (2011). Tumor-associated macrophages promote angiogenesis and melanoma growth via adrenomedullin in both paracrine and autocrine manners. Clin. Cancer Res. 17, 7230-7239.
20. Chiba, S., Baghdadi, M., Akiba, H., Yoshiyama, H., Kinoshita, I., Dosaka-Akita, H., et al. (2012). Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat. Immunol. 13, 832-842.
21. Choi, J. R., Sung, J. H., Shuler, M. L., and Kim, D. (2010). Investigation of portable in situ fluorescence optical detection for microfluidic 3D cell culture assays. Opt. Lett. 35, 1374-1376.
22. Cipponi, A., Mercier, M., Seremet, T., Baurain, J. F., Theate, I., van den Oord, J., et al. (2012). Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer Res. 72, 3997-4007.
23. Clark, W. H. Jr., Elder, D. E., Guerry, D. T., Braitman, L. E., Trock, B. J., Schultz, D., et al. (1989). Model predicting survival in stage I melanoma based on tumor progression. J. Natl. Cancer Inst. 81, 1893-1904.
24. Clausen, J., Vergeiner, B., Enk, M., Petzer, A. L., Gastl, G., and Gunsilius, E. (2003). Functional significance of the activation-associated receptors CD25 and CD69 on human NK-cells and NK-like T-cells. Immunobiology 207, 85-93.
25. Clemente, C. G., Mihm, M. C. Jr., Bufalino, R., Zurrida, S., Collini, P., and Cascinelli, N. (1996). Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77, 1303-1310.
26. Cooke, V. G., Lebleu, V. S., Keskin, D., Khan, Z., O'Connell, J. T., Teng, Y., et al. (2012). Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 21, 66-81.
27. Cordova, A., Toia, F., La Mendola, C., Orlando, V., Meraviglia, S., Rinaldi, G., et al. (2012). Characterization of human gammadelta T lymphocytes infiltrating primary malignant melanomas. PLoS ONE 7:e49878. doi:10.1371/journal.pone.0049878
28. Cox, K., North, M., Burke, M., Singhal, H., Renton, S., Aqel, N., et al. (2005). Plasmacytoid dendritic cells (PDC) are the major DC subset innately producing cytokines in human lymph nodes. J. Leukoc. Biol. 78, 1142-1152.
29. Crowe, N. Y., Coquet, J. M., Berzins, S. P., Kyparissoudis, K., Keating, R., Pellicci, D. G., et al. (2005). Differential antitumor immunity mediated by NKT cell subsets in vivo. J. Exp. Med. 202, 1279-1288.
30. Cui, J., Shin, T., Kawano, T., Sato, H., Kondo, E., Toura, I., et al. (1997). Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 278, 1623-1626.
31. Curran, M. A., Montalvo, W., Yagita, H., and Allison, J. P. (2010). PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. U.S.A. 107, 4275-4280.
32. Danilin, S., Merkel, A. R., Johnson, J. R., Johnson, R. W., Edwards, J. R., and Sterling, J. A. (2012). Myeloid-derived suppressor cells expand during breast cancer progression and promote tumor-induced bone destruction. Oncoimmunology 1, 1484-1494.
33. Daurkin, I., Eruslanov, E., Stoffs, T., Perrin, G. Q., Algood, C., Gilbert, S. M., et al. (2011). Tumor-associated macrophages mediate immunosuppression in the renal cancer microenvironment by activating the 15-lipoxygenase-2 pathway. Cancer Res. 71, 6400-6409.
34. den Haan, J. M., Lehar, S. M., and Bevan, M. J. (2000). CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med. 192, 1685-1696.
35. Diamond, M. S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G. P., Archambault, J. M., et al. (2011). Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208, 1989-2003.
36. Dieu-Nosjean, M. C., Antoine, M., Danel, C., Heudes, D., Wislez, M., Poulot, V., et al. (2008). Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J. Clin. Oncol. 26, 4410-4417.
37. Dvorak, H. F., Weaver, V. M., Tlsty, T. D., and Bergers, G. (2011). Tumor microenvironment and progression. J. Surg. Oncol. 103, 468-474.
38. Eruslanov, E., Daurkin, I., Vieweg, J., Daaka, Y., and Kusmartsev, S. (2011). Aberrant PGE metabolism in bladder tumor microenvironment promotes immunosuppressive phenotype of tumor-infiltrating myeloid cells. Int. Immunopharmacol. 11, 848-855.
39. Exley, M. A., Lynch, L., Varghese, B., Nowak, M., Alatrakchi, N., and Balk, S. P. (2011). Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects. Clin. Immunol. 140, 184-195.
40. Eyles, J., Puaux, A. L., Wang, X., Toh, B., Prakash, C., Hong, M., et al. (2010). Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J. Clin. Invest. 120, 2030-2039.
41. Fabbri, M. (2012). TLRs as miRNA receptors. Cancer Res. 72, 6333-6337.
42. Fabbri, M., Paone, A., Calore, F., Galli, R., Gaudio, E., Santhanam, R., et al. (2012). MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc. Natl. Acad. Sci. U.S.A. 109, E2110-2116.
43. Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L. P., et al. (2011). Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 475, 226-230.
44. Fernandez-Klett, F., Potas, J. R., Hilpert, D., Blazej, K., Radke, J., Huck, J., et al. (2012). Early loss of pericytes and perivascular stromal cell-induced scar formation after stroke. J. Cereb. Blood Flow Metab. 33, 428-439.
45. Finke, J., Ko, J., Rini, B., Rayman, P., Ireland, J., and Cohen, P. (2011). MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int. Immunopharmacol. 11, 856-861.
46. Fridman, W. H., Pages, F., Sautes-Fridman, C., and Galon, J. (2012). The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12, 298-306.
47. Frings, P. W., Van Elssen, C. H., Wieten, L., Matos, C., Hupperets, P. S., Schouten, H. C., et al. (2011). Elimination of the chemotherapy resistant subpopulation of 4T1 mouse breast cancer by haploidentical NK cells cures the vast majority of mice. Breast Cancer Res. Treat. 130, 773-781.
48. Fuertes, M. B., Kacha, A. K., Kline, J., Woo, S. R., Kranz, D. M., Murphy, K. M., et al. (2011). Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J. Exp. Med. 208, 2005-2016.
49. Furumoto, K., Soares, L., Engleman, E. G., and Merad, M. (2004). Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J. Clin. Invest. 113, 774-783.
50. Gabrilovich, D. I., and Nagaraj, S. (2009). Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162-174.
51. Gabrilovich, D. I., Ostrand-Rosenberg, S., and Bronte, V. (2012). Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253-268.
52. Galluzzi, L., Senovilla, L., Vacchelli, E., Eggermont, A., Fridman, W. H., Galon, J., et al. (2012). Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology 1, 1111-1134.
53. Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pages, C., et al. (2006). Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964.
54. Gao, Y., Yang, W., Pan, M., Scully, E., Girardi, M., Augenlicht, L. H., et al. (2003). Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J. Exp. Med. 198, 433-442.
55. Garcia-Iglesias, T., Del Toro-Arreola, A., Albarran-Somoza, B., Del Toro-Arreola, S., Sanchez-Hernandez, P. E., Ramirez-Duenas, M. G., et al. (2009). Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions. BMC Cancer 9:186. doi:10.1186/1471-2407-9-186
56. Gerlini, G., Di Gennaro, P., and Borgognoni, L. (2012a). Enhancing anti-melanoma immunity by electrochemotherapy and in vivo dendritic-cell activation. Oncoimmunology 1, 1655-1657.
57. Gerlini, G., Sestini, S., Di Gennaro, P., Urso, C., Pimpinelli, N., and Borgognoni, L. (2012b). Dendritic cells recruitment in melanoma metastasis treated by electrochemotherapy. Clin. Exp. Metastasis. doi:10.1007/s10585-012-9505-1
58. Girardi, M., Glusac, E., Filler, R. B., Roberts, S. J., Propperova, I., Lewis, J., et al. (2003). The distinct contributions of murine T cell receptor (TCR)gammadelta+ and TCRalphabeta+ T cells to different stages of chemically induced skin cancer. J. Exp. Med. 198, 747-755.
59. Girardi, M., Oppenheim, D. E., Steele, C. R., Lewis, J. M., Glusac, E., Filler, R., et al. (2001). Regulation of cutaneous malignancy by gammadelta T cells. Science 294, 605-609.
60. Gleason, M. K., Verneris, M. R., Todhunter, D. A., Zhang, B., McCullar, V., Zhou, S. X., et al. (2012). Bispecific and trispecific killer cell engagers directly activate human NK Cells through CD16 signaling and induce cytotoxicity and cytokine production. Mol. Cancer Ther. 11, 2674-2684.
61. Godfrey, D. I., Macdonald, H. R., Kronenberg, M., Smyth, M. J., and Van Kaer, L. (2004). NKT cells: what's in a name? Nat. Rev. Immunol. 4, 231-237.
62. Goerge, T., Kleineruschkamp, F., Barg, A., Schnaeker, E. M., Huck, V., Schneider, M. F., et al. (2007). Microfluidic reveals generation of platelet-strings on tumor-activated endothelium. Thromb. Haemost. 98, 283-286.
63. Guo, C. L., Yang, H. C., Yang, X. H., Cheng, W., Dong, T. X., Zhu, W. J., et al. (2012a). Associations between infiltrating lymphocyte subsets and hepatocellular carcinoma. Asian Pac. J. Cancer Prev. 13, 5909-5913.
64. Guo, Q., Lv, Z., Fu, Q., Jiang, C., Liu, Y., Lai, L., et al. (2012b). IFN-gamma producing T cells contribute to the increase of myeloid derived suppressor cells in tumor-bearing mice after cyclophosphamide treatment. Int. Immunopharmacol. 12, 425-432.
65. Gupta, P. B., Chaffer, C. L., and Weinberg, R. A. (2009). Cancer stem cells: mirage or reality? Nat. Med. 15, 1010-1012.
66. Hao, N. B., Lu, M. H., Fan, Y. H., Cao, Y. L., Zhang, Z. R., and Yang, S. M. (2012). Macrophages in tumor microenvironments and the progression of tumors. Clin. Dev. Immunol. 2012, 948098. doi:10.1007/s00424-012-1209-5
67. Hellerbrand, C. (2013). Hepatic stellate cells-the pericytes in the liver. Pflugers Arch.
68. Hervieu, A., Rebe, C., Vegran, F., Chalmin, F., Bruchard, M., Vabres, P., et al. (2012). Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth. J. Invest. Dermatol. doi:10.1038/jid.2012.273
69. Hirao, M., Onai, N., Hiroishi, K., Watkins, S. C., Matsushima, K., Robbins, P. D., et al. (2000). CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res. 60, 2209-2217. doi:10.1074/jbc.M112.441402
70. Hix, L. M., Karavitis, J., Khan, M. W., Shi, Y. H., Khazaie, K., and Zhang, M. (2013). Tumor STAT1 transcription factor activity enhances breast tumor growth and immune suppression mediated by myeloid-derived suppressor cells. J. Biol. Chem.
71. Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723.
72. Huang, H., Zhou, R., Fan, H., Dan, H., Chen, M., Yan, L., et al. (2006). Generation of monoclonal antibodies and epitope mapping of ApxIVA of Actinobacillus pleuropneumoniae. Mol. Immunol. 43, 2130-2134.
73. Iwasaki, K., Komaki, M., Yokoyama, N., Tanaka, Y., Taki, A., Kimura, Y., et al. (2012). Periodontal ligament stem cells possess the characteristics of pericytes. J. Periodontol. doi:10.1902/jop.2012.120547
74. Izhak, L., Ambrosino, E., Kato, S., Parish, S. T., O'Konek, J. J., Weber, H., et al. (2013). Delicate balance among three types of t cells in concurrent regulation of tumor immunity. Cancer Res. 73, 1514-1523.
75. Ji, B., Chen, Q., Liu, B., Wu, L., Tian, D., Guo, Z., et al. (2013). Glioma stem cell-targeted dendritic cells as a tumor vaccine against malignant glioma. Yonsei Med. J. 54, 92-100.
76. Jinushi, M., Chiba, S., Yoshiyama, H., Masutomi, K., Kinoshita, I., Dosaka-Akita, H., et al. (2011). Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc. Natl. Acad. Sci. U.S.A. 108, 12425-12430.
77. Joffre, O. P., Segura, E., Savina, A., and Amigorena, S. (2012). Cross-presentation by dendritic cells. Nat. Rev. Immunol. 12, 557-569.
78. Kabelitz, D., Wesch, D., and He, W. (2007). Perspectives of gammadelta T cells in tumor immunology. Cancer Res. 67, 5-8.
79. Karlsson, R., Michaelsson, A., and Mattsson, L. (1991). Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. J. Immunol. Methods 145, 229-240.
80. Kawano, T., Cui, J., Koezuka, Y., Toura, I., Kaneko, Y., Motoki, K., et al. (1997). CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278, 1626-1629.
81. Ke, Y., Kapp, L. M., and Kapp, J. A. (2003). Inhibition of tumor rejection by gammadelta T cells and IL-10. Cell. Immunol. 221, 107-114.
82. Kee, J. Y., Ito, A., Hojo, S., Hashimoto, I., Igarashi, Y., Tsukada, K., et al. (2013). Chemokine CXCL16 suppresses liver metastasis of colorectal cancer via augmentation of tumor-infiltrating natural killer T cells in a murine model. Oncol. Rep. 29, 975-982.
83. Kerkar, S. P., and Restifo, N. P. (2012). Cellular constituents of immune escape within the tumor microenvironment. Cancer Res. 72, 3125-3130.
84. Kim, H., Kim, S. H., Kim, M. J., Kim, S. J., Park, S. J., Chung, J. S., et al. (2011). EGFR inhibitors enhanced the susceptibility to NK cell-mediated lysis of lung cancer cells. J. Immunother. 34, 372-381.
85. Kim, J., Taylor, D., Agrawal, N., Wang, H., Kim, H., Han, A., et al. (2012). A programmable microfluidic cell array for combinatorial drug screening. Lab. Chip 12, 1813-1822.
86. Kmieciak, M., Basu, D., Payne, K. K., Toor, A., Yacoub, A., Wang, X. Y., et al. (2011). Activated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse. J. Immunol. 187, 708-717.
87. Kronenberg, M. (2005). Toward an understanding of NKT cell biology: progress and paradoxes. Annu. Rev. Immunol. 23, 877-900.
88. Kurts, C., Robinson, B. W., and Knolle, P. A. (2010). Cross-priming in health and disease. Nat. Rev. Immunol. 10, 403-414.
89. Ladanyi, A., Kiss, J., Somlai, B., Gilde, K., Fejos, Z., Mohos, A., et al. (2007). Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol. Immunother. 56, 1459-1469.
90. Lakshmikanth, T., Burke, S., Ali, T. H., Kimpfler, S., Ursini, F., Ruggeri, L., et al. (2009). NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J. Clin. Invest. 119, 1251-1263.
91. Levy, E. M., Roberti, M. P., and Mordoh, J. (2011). Natural killer cells in human cancer: from biological functions to clinical applications. J. Biomed. Biotechnol. 2011:676198. doi:10.1155/2011/676198
92. Li, J., Nandagopal, S., Wu, D., Romanuik, S. F., Paul, K., Thomson, D. J., et al. (2011). Activated T lymphocytes migrate toward the cathode of DC electric fields in microfluidic devices. Lab. Chip 11, 1298-1304.
93. Li, P. C., and Harrison, D. J. (1997). Transport, manipulation, and reaction of biological cells on-chip using electrokinetic effects. Anal. Chem. 69, 1564-1568.
94. Li, X., Wu, Z., Fu, X., and Han, W. (2013). A microRNA component of the neoplastic microenvironment: microregulators with far-reaching impact. Biomed. Res. Int. 2013, 762183.
95. Lin, F., Nguyen, C. M., Wang, S. J., Saadi, W., Gross, S. P., and Jeon, N. L. (2004). Effective neutrophil chemotaxis is strongly influenced by mean IL-8 concentration. Biochem. Biophys. Res. Commun. 319, 576-581.
96. Liu, D., Song, L., Wei, J., Courtney, A. N., Gao, X., Marinova, E., et al. (2012). IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity. J. Clin. Invest. 122, 2221-2233.
97. Liu, J., Zhang, N., Li, Q., Zhang, W., Ke, F., Leng, Q., et al. (2011). Tumor-associated macrophages recruit CCR6+ regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice. PLoS ONE 6:e19495. doi:10.1371/journal.pone.0019495
98. Liu, J. Y., Wu, Y., Zhang, X. S., Yang, J. L., Li, H. L., Mao, Y. Q., et al. (2007). Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine. Cancer Immunol. Immunother. 56, 1597-1604.
99. Lorenzi, S., Mattei, F., Sistigu, A., Bracci, L., Spadaro, F., Sanchez, M., et al. (2011). Type I IFNs control antigen retention and survival of CD8{alpha}+ dendritic cells after uptake of tumor apoptotic cells leading to cross-priming. J. Immunol. 186, 5142-5150.
100. Ma, C., Zhang, Q., Ye, J., Wang, F., Zhang, Y., Wevers, E., et al. (2012). Tumor-infiltrating gammadelta T lymphocytes predict clinical outcome in human breast cancer. J. Immunol. 189, 5029-5036.
101. Ma, Y., Aymeric, L., Locher, C., Mattarollo, S. R., Delahaye, N. F., Pereira, P., et al. (2011). Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J. Exp. Med. 208, 491-503.
102. Martinez, F. O., Helming, L., and Gordon, S. (2009). Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 27, 451-483.
103. Mattarollo, S. R., Loi, S., Duret, H., Ma, Y., Zitvogel, L., and Smyth, M. J. (2011). Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res. 71, 4809-4820.
104. Mattei, F., and Schiavoni, G. (2013). TIM-3 as a molecular switch for tumor escape from innate immunity. Front. Immunol. 3:418. doi:10.3389/fimmu.2012.00418
105. Mattei, F., Schiavoni, G., Sestili, P., Spadaro, F., Fragale, A., Sistigu, A., et al. (2012). IRF-8 controls melanoma progression by regulating the crosstalk between cancer and immune cells within the tumor microenvironment. Neoplasia 14, 1223-1235.
106. Mempel, T. R., and Bauer, C. A. (2009). Intravital imaging of CD8+ T cell function in cancer. Clin. Exp. Metastasis 26, 311-327.
107. Menetrier-Caux, C., Curiel, T., Faget, J., Manuel, M., Caux, C., and Zou, W. (2012a). Targeting regulatory T cells. Target. Oncol. 7, 15-28.
108. Menetrier-Caux, C., Faget, J., Biota, C., Gobert, M., Blay, J. Y., and Caux, C. (2012b). Innate immune recognition of breast tumor cells mediates CCL22 secretion favoring Treg recruitment within tumor environment. Oncoimmunology 1, 759-761.
109. Metelitsa, L. S. (2011). Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans. Clin. Immunol. 140, 119-129.
110. Metelitsa, L. S., Wu, H. W., Wang, H., Yang, Y., Warsi, Z., Asgharzadeh, S., et al. (2004). Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J. Exp. Med. 199, 1213-1221.
111. Michielsen, A. J., Hogan, A. E., Marry, J., Tosetto, M., Cox, F., Hyland, J. M., et al. (2011). Tumour tissue microenvironment can inhibit dendritic cell maturation in colorectal cancer. PLoS ONE 6:e27944. doi:10.1371/journal.pone.0027944
112. Michielsen, A. J., Ryan, E. J., and O'Sullivan, J. N. (2012). Dendritic cell inhibition correlates with survival of colorectal cancer patients on bevacizumab treatment. Oncoimmunology 1, 1445-1447.
113. Miescher, S., Schreyer, M., Barras, C., Capasso, P., and von Fliedner, V. (1990). Sparse distribution of gamma/delta T lymphocytes around human epithelial tumors predominantly infiltrated by primed/memory T cells. Cancer Immunol. Immunother. 32, 81-87.
114. Milush, J. M., Long, B. R., Snyder-Cappione, J. E., Cappione, A. J. III, York, V. A., Ndhlovu, L. C., et al. (2009). Functionally distinct subsets of human NK cells and monocyte/DC-like cells identified by coexpression of CD56, CD7, and CD4. Blood 114, 4823-4831.
115. Minato, N., Reid, L., and Bloom, B. R. (1981). On the heterogeneity of murine natural killer cells. J. Exp. Med. 154, 750-762.
116. Mitchem, J. B., Brennan, D. J., Knolhoff, B. L., Belt, B. A., Zhu, Y., Sanford, D. E., et al. (2012). Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression and improves chemotherapeutic response. Cancer Res. doi:10.1158/0008-5472.CAN-12-2731
117. Morandi, B., Mortara, L., Chiossone, L., Accolla, R. S., Mingari, M. C., Moretta, L., et al. (2012). Dendritic cell editing by activated natural killer cells results in a more protective cancer-specific immune response. PLoS ONE 7:e39170. doi:10.1371/journal.pone.0039170
118. Moretta, A. (2002). Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat. Rev. Immunol. 2, 957-964.
119. Moretta, L., Ferlazzo, G., Bottino, C., Vitale, M., Pende, D., Mingari, M. C., et al. (2006). Effector and regulatory events during natural killer-dendritic cell interactions. Immunol. Rev. 214, 219-228.
120. Nagato, K., Motohashi, S., Ishibashi, F., Okita, K., Yamasaki, K., Moriya, Y., et al. (2012). Accumulation of activated invariant natural killer T cells in the tumor microenvironment after alpha-galactosylceramide-pulsed antigen presenting cells. J. Clin. Immunol. 32, 1071-1081.
121. Naito, Y., Saito, K., Shiiba, K., Ohuchi, A., Saigenji, K., Nagura, H., et al. (1998). CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 58, 3491-3494.
122. Nakagawa, R., Serizawa, I., Motoki, K., Sato, M., Ueno, H., Iijima, R., et al. (2000). Antitumor activity of alpha-galactosylceramide, KRN7000, in mice with the melanoma B16 hepatic metastasis and immunohistological study of tumor infiltrating cells. Oncol. Res. 12, 51-58.
123. Osada, T., Nagawa, H., and Shibata, Y. (2004). Tumor-infiltrating effector cells of alpha-galactosylceramide-induced antitumor immunity in metastatic liver tumor. J. Immune Based Ther. Vaccines 2, 7.
124. Pardo, J., Aguilo, J. I., Anel, A., Martin, P., Joeckel, L., Borner, C., et al. (2009). The biology of cytotoxic cell granule exocytosis pathway: granzymes have evolved to induce cell death and inflammation. Microbes Infect. 11, 452-459.
125. Pardoll, D. (2003). Does the immune system see tumors as foreign or self? Annu. Rev. Immunol. 21, 807-839.
126. Park, B. G., Park, C. J., Yoon, C. H., Jang, S., Chi, H. S., Ryu, M. H., et al. (2012a). The extended leukocyte differential count using the cytodiff flow cytometric system reveals that higher CD16+ cytotoxic NK+T lymphocyte levels predict superior survival outcomes in patients with metastatic carcinoma. Cytometry B Clin. Cytom. doi:10.1002/cyto.b.21063
127. Park, H. J., Kusnadi, A., Lee, E. J., Kim, W. W., Cho, B. C., Lee, I. J., et al. (2012b). Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors. Cell. Immunol. 278, 76-83.
128. Park, M. H., Lee, J. S., and Yoon, J. H. (2012c). High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumor-infiltrating CD8+ T cells, natural killer cells, and dendritic cells in breast carcinoma. J. Surg. Oncol. 106, 386-392.
129. Penuelas, S., Anido, J., Prieto-Sanchez, R. M., Folch, G., Barba, I., Cuartas, I., et al. (2009). TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 15, 315-327.
130. Pfeiffer, M., Seitz, G., Ruck, P., Mueller, C., Steinle, A., Lang, P., et al. (2011). CD155 is involved in NK-cell mediated lysis of human hepatoblastoma in vitro. Front. Biosci. (Elite Ed.) 3, 1456-1466.
131. Pham-Nguyen, K. B., Yang, W., Saxena, R., Thung, S. N., Woo, S. L., and Chen, S. H. (1999). Role of NK and T cells in IL-12-induced anti-tumor response against hepatic colon carcinoma. Int. J. Cancer 81, 813-819.
132. Pietra, G., Manzini, C., Vitale, M., Balsamo, M., Ognio, E., Boitano, M., et al. (2009). Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. Int. Immunol. 21, 793-801.
133. Pietra, G., Vitale, M., Moretta, L., and Mingari, M. C. (2012). How melanoma cells inactivate NK cells. Oncoimmunology 1, 974-975.
134. Platonova, S., Cherfils-Vicini, J., Damotte, D., Crozet, L., Vieillard, V., Validire, P., et al. (2011). Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res. 71, 5412-5422.
135. Pollard, J. W. (2009). Trophic macrophages in development and disease. Nat. Rev. Immunol. 9, 259-270.
136. Preynat-Seauve, O., Schuler, P., Contassot, E., Beermann, F., Huard, B., and French, L. E. (2006). Tumor-infiltrating dendritic cells are potent antigen-presenting cells able to activate T cells and mediate tumor rejection. J. Immunol. 176, 61-67.
137. Quezada, S. A., Peggs, K. S., Simpson, T. R., and Allison, J. P. (2011). Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol. Rev. 241, 104-118.
138. Quintana, E., Shackleton, M., Sabel, M. S., Fullen, D. R., Johnson, T. M., and Morrison, S. J. (2008). Efficient tumour formation by single human melanoma cells. Nature 456, 593-598.
139. Ren, S., Johnson, B. G., Kida, Y., Ip, C., Davidson, K. C., Lin, S. L., et al. (2013). LRP-6 is a coreceptor for multiple fibrogenic signaling pathways in pericytes and myofibroblasts that are inhibited by DKK-1. Proc. Natl. Acad. Sci. U.S.A. doi:10.1073/pnas.1211179110
140. Roberti, M. P., Mordoh, J., and Levy, E. M. (2012a). Biological role of NK cells and immunotherapeutic approaches in breast cancer. Front. Immunol. 3:375. doi:10.3389/fimmu.2012.00375
141. Roberti, M. P., Rocca, Y. S., Amat, M., Pampena, M. B., Loza, J., Colo, F., et al. (2012b). IL-2-or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients. Breast Cancer Res. Treat. 136, 659-671.
142. Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., and Anderson, A. C. (2010). Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207, 2187-2194.
143. Sato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., et al. (2005). Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. U.S.A. 102, 18538-18543.
144. Schlecker, E., Stojanovic, A., Eisen, C., Quack, C., Falk, C. S., Umansky, V., et al. (2012). Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J. Immunol. 189, 5602-5611.
145. Schumacher, K., Haensch, W., Roefzaad, C., and Schlag, P. M. (2001). Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res. 61, 3932-3936.
146. Schwarz, E. C., Qu, B., and Hoth, M. (2012). Calcium, cancer and killing: the role of calcium in killing cancer cells by cytotoxic T lymphocytes and natural killer cells. Biochim. Biophys. Acta. doi:10.1016/j.bbamcr.2012.11.016
147. Sengupta, A., and Cancelas, J. A. (2010). Cancer stem cells: a stride towards cancer cure? J. Cell. Physiol. 225, 7-14.
148. Senovilla, L., Vacchelli, E., Galon, J., Adjemian, S., Eggermont, A., Fridman, W. H., et al. (2012). Trial watch: prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 1, 1323-1343.
149. Seo, N., Tokura, Y., Takigawa, M., and Egawa, K. (1999). Depletion of IL-10-and TGF-beta-producing regulatory gamma delta T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells. J. Immunol. 163, 242-249.
150. Serafini, P., De Santo, C., Marigo, I., Cingarlini, S., Dolcetti, L., Gallina, G., et al. (2004). Derangement of immune responses by myeloid suppressor cells. Cancer Immunol. Immunother. 53, 64-72.
151. Shackleton, M., and Quintana, E. (2010). Progress in understanding melanoma propagation. Mol. Oncol. 4, 451-457.
152. Shurin, M. R., Shurin, G. V., Lokshin, A., Yurkovetsky, Z. R., Gutkin, D. W., Chatta, G., et al. (2006). Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies? Cancer Metastasis Rev. 25, 333-356.
153. Simpson, K. D., Templeton, D. J., and Cross, J. V. (2012). Macrophage migration inhibitory factor promotes tumor growth and metastasis by inducing myeloid-derived suppressor cells in the tumor microenvironment. J. Immunol. 189, 5533-5540.
154. Sinha, P., Clements, V. K., and Ostrand-Rosenberg, S. (2005). Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J. Immunol. 174, 636-645.
155. Siyan, W., Feng, Y., Lichuan, Z., Jiarui, W., Yingyan, W., Li, J., et al. (2009). Application of microfluidic gradient chip in the analysis of lung cancer chemotherapy resistance. J. Pharm. Biomed. Anal. 49, 806-810.
156. Smyth, M. J., and Godfrey, D. I. (2000). NKT cells and tumor immunity-a double-edged sword. Nat. Immunol. 1, 459-460.
157. Solinas, G., Germano, G., Mantovani, A., and Allavena, P. (2009). Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J. Leukoc. Biol. 86, 1065-1073.
158. Solito, S., Falisi, E., Diaz-Montero, C. M., Doni, A., Pinton, L., Rosato, A., et al. (2011). A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood 118, 2254-2265.
159. Srivastava, A. K., Sharma, R. K., Yolcu, E. S., Ulker, V., Macleod, K., Dinc, G., et al. (2012). Prime-boost vaccination with SA-4-1BBL costimulatory molecule and survivin eradicates lung carcinoma in CD8+ T and NK cell dependent manner. PLoS ONE 7:e48463. doi:10.1371/journal.pone.0048463
160. Stark, K., Eckart, A., Haidari, S., Tirniceriu, A., Lorenz, M., von Bruhl, M. L., et al. (2013). Capillary and arteriolar pericytes attract innate leukocytes exiting through venules and "instruct" them with pattern-recognition and motility programs. Nat. Immunol. 14, 41-51.
161. Swann, J., Crowe, N. Y., Hayakawa, Y., Godfrey, D. I., and Smyth, M. J. (2004). Regulation of antitumour immunity by CD1d-restricted NKT cells. Immunol. Cell Biol. 82, 323-331.
162. Tachibana, T., Onodera, H., Tsuruyama, T., Mori, A., Nagayama, S., Hiai, H., et al. (2005). Increased intratumor Valpha24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. Clin. Cancer Res. 11, 7322-7327.
163. Takeda, K., Nakayama, M., Sakaki, M., Hayakawa, Y., Imawari, M., Ogasawara, K., et al. (2011). IFN-gamma production by lung NK cells is critical for the natural resistance to pulmonary metastasis of B16 melanoma in mice. J. Leukoc. Biol. 90, 777-785.
164. Takemura, S., Braun, A., Crowson, C., Kurtin, P. J., Cofield, R. H., O'Fallon, W. M., et al. (2001). Lymphoid neogenesis in rheumatoid synovitis. J. Immunol. 167, 1072-1080.
165. Tarazona, R., Casado, J. G., Soto, R., Delarosa, O., Peralbo, E., Rioja, L., et al. (2004). Expression of NK-associated receptors on cytotoxic T cells from melanoma patients: a two-edged sword? Cancer Immunol. Immunother. 53, 911-924.
166. Terabe, M., Matsui, S., Noben-Trauth, N., Chen, H., Watson, C., Donaldson, D. D., et al. (2000). NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol. 1, 515-520.
167. Terabe, M., Matsui, S., Park, J. M., Mamura, M., Noben-Trauth, N., Donaldson, D. D., et al. (2003). Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198, 1741-1752.
168. Terabe, M., Swann, J., Ambrosino, E., Sinha, P., Takaku, S., Hayakawa, Y., et al. (2005). A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J. Exp. Med. 202, 1627-1633.
169. Toh, B., Chew, V., Dai, X., Khoo, K., Tham, M., Wai, L. E., et al. (2012). Immune predictors of cancer progression. Immunol. Res. 53, 229-234.
170. Turnquist, H. R., Lin, X., Ashour, A. E., Hollingsworth, M. A., Singh, R. K., Talmadge, J. E., et al. (2007). CCL21 induces extensive intratumoral immune cell infiltration and specific anti-tumor cellular immunity. Int. J. Oncol. 30, 631-639.
171. Van Ginderachter, J. A., Movahedi, K., Hassanzadeh Ghassabeh, G., Meerschaut, S., Beschin, A., Raes, G., et al. (2006). Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion. Immunobiology 211, 487-501.
172. van Houdt, I. S., Sluijter, B. J., Moesbergen, L. M., Vos, W. M., De Gruijl, T. D., Molenkamp, B. G., et al. (2008). Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression. Int. J. Cancer 123, 609-615.
173. Van Kaer, L. (2007). NKT cells: T lymphocytes with innate effector functions. Curr. Opin. Immunol. 19, 354-364.
174. Vasquez-Dunddel, D., Pan, F., Zeng, Q., Gorbounov, M., Albesiano, E., Fu, J., et al. (2013). STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J. Clin. Invest. doi:10.1172/JCI60083
175. Velthuis, J. H., Stitzinger, M., Aalbers, R. I., De Bont, H. J., Mulder, G. J., Kuppen, P. J., et al. (2003). Rat colon carcinoma cells that survived systemic immune surveillance are less sensitive to NK-cell mediated apoptosis. Clin. Exp. Metastasis 20, 713-721.
176. Vesely, M. D., Kershaw, M. H., Schreiber, R. D., and Smyth, M. J. (2011). Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29, 235-271.
177. Vicari, A. P., Chiodoni, C., Vaure, C., Ait-Yahia, S., Dercamp, C., Matsos, F., et al. (2002). Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J. Exp. Med. 196, 541-549.
178. Viola, A., Sarukhan, A., Bronte, V., and Molon, B. (2012). The pros and cons of chemokines in tumor immunology. Trends Immunol. 33, 496-504.
179. Visvader, J. E., and Lindeman, G. J. (2008). Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 8, 755-768.
180. Wakita, D., Sumida, K., Iwakura, Y., Nishikawa, H., Ohkuri, T., Chamoto, K., et al. (2010). Tumor-infiltrating IL-17-producing gammadelta T cells support the progression of tumor by promoting angiogenesis. Eur. J. Immunol. 40, 1927-1937.
181. Wang, X., Cui, Y., Luo, G., Wang, Q., Hu, J., He, W., et al. (2012a). Activated mouse CD4(+)Foxp3(-) T cells facilitate melanoma metastasis via Qa-1-dependent suppression of NK-cell cytotoxicity. Cell Res. 22, 1696-1706.
182. Wang, Y., Ma, Y., Fang, Y., Wu, S., Liu, L., Fu, D., et al. (2012b). Regulatory T cell: a protection for tumour cells. J. Cell. Mol. Med. 16, 425-436.
183. Ward, P. L., Koeppen, H. K., Hurteau, T., Rowley, D. A., and Schreiber, H. (1990). Major histocompatibility complex class I and unique antigen expression by murine tumors that escaped from CD8+ T-cell-dependent surveillance. Cancer Res. 50, 3851-3858.
184. Weigelin, B., Krause, M., and Friedl, P. (2011). Cytotoxic T lymphocyte migration and effector function in the tumor microenvironment. Immunol. Lett. 138, 19-21.
185. Weng, D., Song, B., Durfee, J., Sugiyama, V., Wu, Z., Koido, S., et al. (2011). Induction of cytotoxic T lymphocytes against ovarian cancer-initiating cells. Int. J. Cancer 129, 1990-2001.
186. Wilding, P., Pfahler, J., Bau, H. H., Zemel, J. N., and Kricka, L. J. (1994). Manipulation and flow of biological fluids in straight channels micromachined in silicon. Clin. Chem. 40, 43-47.
187. Wlodkowic, D., and Cooper, J. M. (2010). Tumors on chips: oncology meets microfluidics. Curr. Opin. Chem. Biol. 14, 556-567.
188. Wlodkowic, D., and Darzynkiewicz, Z. (2010). Microfluidics: emerging prospects for anti-cancer drug screening. World J. Clin. Oncol. 1, 18-23.
189. Wong, A. P., Perez-Castillejos, R., Christopher Love, J., and Whitesides, G. M. (2008). Partitioning microfluidic channels with hydrogel to construct tunable 3-D cellular microenvironments. Biomaterials 29, 1853-1861.
190. Wu, Y. J., Tian, W. T., Snider, R. M., Rittershaus, C., Rogers, P., Lamanna, L., et al. (1988). Signal transduction of gamma/delta T cell antigen receptor with a novel mitogenic anti-delta antibody. J. Immunol. 141, 1476-1479.
191. Xia, J., Chen, X., Zhou, C. Z., Li, Y. G., and Peng, Z. H. (2011). Development of a low-cost magnetic microfluidic chip for circulating tumour cell capture. IET Nanobiotechnol. 5, 114-120.
192. Yasuda, H., Aritaka, N., Ando, J., Hirama, M., Komatsu, N., and Hirano, T. (2011). Chronic myelogenous leukemia with mild basophilia as the predominant manifestation at presentation. Intern. Med. 50, 501-502.
193. Ye, X. Z., Yu, S. C., and Bian, X. W. (2010). Contribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasis. J. Genet. Genomics 37, 423-430.
194. Yu, X., Li, H., and Ren, X. (2012). Interaction between regulatory T cells and cancer stem cells. Int. J. Cancer 131, 1491-1498.
195. Yusuf, N., Nasti, T. H., Katiyar, S. K., Jacobs, M. K., Seibert, M. D., Ginsburg, A. C., et al. (2008). Antagonistic roles of CD4+ and CD8+ T-cells in 7,12-dimethylbenz(a)anthracene cutaneous carcinogenesis. Cancer Res. 68, 3924-3930.
196. Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., et al. (2003). Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203-213.
197. Zhang, Y., Lv, D., Kim, H. J., Kurt, R. A., Bu, W., Li, Y., et al. (2012). A novel role of hematopoietic CCL5 in promoting triple-negative mammary tumor progression by regulating generation of myeloid-derived suppressor cells. Cell Res. 23, 394-408.